Why the future of marijuana legalization remains hazy despite high public support 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
The four types of dementia most people don’t know exist 
US Launches New Trade Investigation Into Vietnam Over Intellectual Property Concerns 
US Southern Command Chief Holds Rare Military Meeting With Cuban Officials at Guantanamo Bay 
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
US Plans Faster Military Drawdown in Europe, NATO Allies Face Greater Defense Role 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
US Designates Brazil’s PCC and Comando Vermelho as Global Terrorist Entities Ahead of FTO Listing 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
US Tightens Ebola Controls as Congo Outbreak Sparks Global Concern 
Iran-U.S. Nuclear Talks Remain Unresolved as Strait of Hormuz Risks Keep Markets on Edge 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
US Condemns Russia’s Oreshnik Missile Strike, Warns Against New Attacks on Kyiv 
China Expands Nuclear Defense Network in Remote Desert 
The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is facing leadership uncertainty after acting director Jeffery Taubenberger stepped down during ongoing Ebola and hantavirus outbreak concerns. The departure was revealed Thursday during a Senate hearing on the National Institutes of Health (NIH) 2027 budget, sparking criticism from Democratic lawmakers over the agency’s preparedness for emerging infectious diseases.
Taubenberger assumed the acting director role in April 2025 after the Trump administration removed former NIAID leadership. Senator Tammy Baldwin announced his resignation at the hearing, while Senator Patty Murray also referenced the sudden exit. NIH Director Jay Bhattacharya did not deny the reports and said the agency is shifting priorities away from civilian biodefense and pandemic preparedness toward direct infectious disease response, allergy research, and immunology.
The leadership change comes as global health officials monitor an Ebola outbreak in the Democratic Republic of Congo and potential hantavirus exposure linked to a luxury cruise ship outbreak in the Atlantic Ocean. Although no confirmed U.S. cases of Andes hantavirus have been reported, 41 individuals, including 18 people quarantined in Nebraska, remain under observation.
Former NIAID director Jeanne Marrazzo criticized the current situation, warning that the institute appears disconnected from researchers and pharmaceutical companies working on Ebola treatments. Under former director Anthony Fauci, NIAID played a major role in managing both the COVID-19 pandemic and the 2014-2016 Ebola crisis in West Africa.
The latest departures add to growing concerns about instability within the NIH, where more than half of its 27 institutes are currently overseen by acting directors. NIAID, the NIH’s second-largest institute with a budget exceeding $6.5 billion, remains central to U.S. infectious disease research and public health response efforts.
